GLP-1 drugs like Ozempic, while effective for significant weight loss and reducing chronic disease risk, are associated with emerging side effects. Rapid weight loss can lead to ‘Ozempic mouth,’ characterized by hollowing around the mouth, deeper lines, and a prematurely aged appearance due to skin laxity.
American Heart Association by Laura Williamson, American Heart Association NewsPublished: January 14, 2025 The American Heart Association discusses healthspan, defining it as the number of years one lives free from significant chronic disease or disability, and contrasts it with life expectancy. It highlights the concerning trend of shrinking healthspans in the U.S. despite recent rebounds in … Read more
Novo Nordisk scored a major win in its wide-ranging legal fight to keep compounders from making copies of its obesity drug semaglutide. A federal district court in Texas on Thursday denied a request for a …
In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk for falls, and combined use with GLP-1 RAs nearly tripled the risk. Medscape Medical News
In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published April 23 in the American Journal of Health-System Pharmacy, reviewed the IQVIA National Sales Perspectives database, which tracks medication purchases by hospitals, clinics, retail pharmacies, mail-order … Read more